Duncan Bridgeman
|
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
Devon Funds Morning Note - 04 May 2026
MEL - Meridian joins global ranks of sustainable companies
May 5th Morning Report
ATM - a2MC recalls small volume of a2 Platinum USA label
CEN - Contact Chair to retire this year, new Chair appointed
May 1st Morning Report
GTK - Gentrack's Veovo Acquires Dubai Technology Partners
SML - Additional information following Bright Dairy announcement
April 30th Morning Report
Rua Bioscience Market Update